ICY Stock Chart & Stats
CHF94.02
CHF0.00(0.00%)
At close: 4:00 PM EDT
CHF94.02
CHF0.00(0.00%)
Day’s Range― - ―
52-Week RangeCHF88.30 - CHF104.88
Previous CloseN/A
Volume0.00
Average Volume (3M)2.00
Market Cap
CHF20.89B
Enterprise ValueCHF19.11K
Total Cash (Recent Filing)CHF4.54B
Total Debt (Recent Filing)CHF38.27M
Price to Earnings (P/E)15.7
Beta1.86
Next Earnings
Nov 03, 2026EPS Estimate
-2.26Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)8.13
Shares Outstanding202,697,740
10 Day Avg. Volume2
30 Day Avg. Volume2
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)3.73
Price to Sales (P/S)3.75
P/FCF Ratio14.23
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
CHF105.32Price Target Upside12.02% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering21
EPS Forecast (FY)3.11
Revenue Forecast (FY)CHF4.75B
Bulls Say, Bears Say
Bulls Say
Diversified Commercial GrowthGrowth is broadening beyond the mature Jakafi franchise, with Opzelura, hematology products and international launches contributing. This diversification can reduce dependence on one product and support a more durable commercial revenue base over the next several years.
Strong Cash Generation And Balance SheetRobust cash generation and minimal leverage give Incyte substantial flexibility to fund research, acquisitions and commercialization without relying heavily on external capital. This strengthens resilience if clinical programs disappoint or operating expenses remain elevated.
Expanded Late-stage Hematology PipelineVGA039 adds a differentiated, late-stage asset in rare hematology and expands Incyte beyond oncology and dermatology. If clinical and regulatory milestones are achieved, the program could create a meaningful future growth driver and broaden the company’s therapeutic reach.
Bears Say
Reported Growth Includes A One-time BenefitThe settlement improves economics by ending certain accruals, but it is not recurring product demand or cash revenue. Underlying growth is therefore weaker than reported figures suggest, making future comparisons and the durability of guidance more dependent on sustained prescription expansion.
Higher Investment Burden May Pressure MarginsThe acquisition and accelerated late-stage development increase near-term costs substantially. Although these investments may build future revenue, they can reduce operating leverage, weigh on cash conversion and raise execution risk before new products generate offsetting commercial returns.
Clinical And Regulatory Execution RiskPipeline value depends on uncertain trial outcomes, regulatory decisions and differentiation against competing therapies. The 058 discontinuation removes a near-term JAK2 option, while later-stage assets may take years to mature, increasing reliance on successful execution across several programs.
Incyte News
ICY FAQ
What was Incyte Corp’s price range in the past 12 months?
Incyte Corp lowest stock price was CHF88.30 and its highest was CHF104.88 in the past 12 months.
What is Incyte Corp’s market cap?
Incyte Corp’s market cap is CHF20.89B.
When is Incyte Corp’s upcoming earnings report date?
Incyte Corp’s upcoming earnings report date is Nov 03, 2026 which is in 67 days.
How were Incyte Corp’s earnings last quarter?
Incyte Corp released its earnings results on Jul 28, 2026. The company reported CHF2.469 earnings per share for the quarter, beating the consensus estimate of CHF1.755 by CHF0.714.
Is Incyte Corp overvalued?
According to Wall Street analysts Incyte Corp’s price is currently Undervalued.
Does Incyte Corp pay dividends?
Incyte Corp does not currently pay dividends.
What is Incyte Corp’s EPS estimate?
Incyte Corp’s EPS estimate is -2.26.
How many shares outstanding does Incyte Corp have?
Incyte Corp has 202,697,740 shares outstanding.
What happened to Incyte Corp’s price movement after its last earnings report?
Incyte Corp reported an EPS of CHF2.469 in its last earnings report, beating expectations of CHF1.755. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Incyte Corp?
Currently, no hedge funds are holding shares in CH:ICY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Incyte Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
CHF105.32 (12.02% Upside)
CHF105.32 (12.02% Upside)
Blogger Sentiment
Bullish
CH:ICY Sentiment 82%
Sector Average 60%
Sector Average 60%
Insider Transactions
Sold Shares
Worth CHF15.1M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
66.93%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
35.24%
Trailing 12-Months
Company Description
Incyte Corp
Incyte Corporation is a biopharmaceutical firm engaged in the research, development, and global marketing of its own innovative therapies. Its current product offerings include JAKAFI, prescribed for myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that targets oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor utilized for chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia. Beyond its marketed drugs, Incyte's pipeline features several promising candidates. Among its clinical-stage assets are ruxolitinib, targeting steroid-refractory chronic graft-versus-host disease (GVHD), and itacitinib, which is undergoing Phase II/III trials for newly diagnosed chronic GVHD. Pemigatinib is also being investigated for conditions such as bladder cancer, cholangiocarcinoma, myeloproliferative syndrome, and other tumor types. Further advancing its research, the company is developing Parsaclisib, currently in Phase II studies for follicular lymphoma, marginal zone lymphoma, and mantle cell lymphoma. Additionally, Retifanlimab is in Phase II development for multiple indications, including MSI-high endometrial cancer, Merkel cell carcinoma, anal cancer, and non-small cell lung cancer. Incyte maintains a broad network of strategic alliances with numerous pharmaceutical and biotech companies, including key partners like Novartis International Pharmaceutical Ltd., Eli Lilly and Company, and Agenus Inc., among many others. These collaborations extend to clinical trials, notably joint efforts with MorphoSys AG and Xencor, Inc., to evaluate a combination therapy involving tafasitamab, plamotamab, and lenalidomide for patients with recurrent or resistant diffuse large B-cell lymphoma and follicular lymphoma. Established in 1991, the corporation's main offices are situated in Wilmington, Delaware.
ICY Company Deck
ICY Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented strong commercial momentum and meaningful pipeline maturation: double-digit and multi-factor sales growth (notably Opzelura and core products), multiple regulatory milestones and new Phase III starts, a strategic acquisition adding a high-potential hematology asset, and an upward revision to full-year revenue guidance. Offsetting these positives are reliance on a one-time CMS settlement that materially boosted near-term results and guidance, the discontinuation of the 058 JAK2 program, and materially higher near-term operating expenses driven by acquisition-related charges and expanded late-stage investments. Management emphasized execution risk, reimbursement dynamics and regulatory discussions that remain unresolved for some programs. Overall, the highlights — broad commercial growth, pipeline progression and strengthened late-stage portfolio — outweigh the lowlights, though near-term margin and execution risks merit monitoring.View all CH:ICY earnings summariesICY Revenue Breakdown
84.69% Product revenues, net
12.39% Product royalty revenues
2.92% Milestone and contract revenues
ICY Stock 12 Month Forecast
Average Price Target
CHF105.32
▲(12.02% Upside)